[go: up one dir, main page]

PL3999038T3 - Preparaty doustne inhibitora sarkomerów sercowych - Google Patents

Preparaty doustne inhibitora sarkomerów sercowych

Info

Publication number
PL3999038T3
PL3999038T3 PL20753563.4T PL20753563T PL3999038T3 PL 3999038 T3 PL3999038 T3 PL 3999038T3 PL 20753563 T PL20753563 T PL 20753563T PL 3999038 T3 PL3999038 T3 PL 3999038T3
Authority
PL
Poland
Prior art keywords
oral formulations
cardiac sarcomere
inhibitor oral
inhibitor
sarcomere
Prior art date
Application number
PL20753563.4T
Other languages
English (en)
Inventor
Chunsheng Qiao
Original Assignee
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics, Inc. filed Critical Cytokinetics, Inc.
Publication of PL3999038T3 publication Critical patent/PL3999038T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20753563.4T 2019-07-17 2020-07-16 Preparaty doustne inhibitora sarkomerów sercowych PL3999038T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875358P 2019-07-17 2019-07-17
PCT/US2020/042389 WO2021011808A1 (en) 2019-07-17 2020-07-16 Cardiac sarcomere inhibitor oral formulations

Publications (1)

Publication Number Publication Date
PL3999038T3 true PL3999038T3 (pl) 2024-05-13

Family

ID=71995104

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20753563.4T PL3999038T3 (pl) 2019-07-17 2020-07-16 Preparaty doustne inhibitora sarkomerów sercowych

Country Status (25)

Country Link
US (1) US20220265612A1 (pl)
EP (1) EP3999038B1 (pl)
JP (1) JP7623342B2 (pl)
KR (1) KR20220082804A (pl)
CN (1) CN114765954B (pl)
AU (1) AU2020315642A1 (pl)
BR (1) BR112022000495A2 (pl)
CA (1) CA3144972A1 (pl)
CL (1) CL2022000108A1 (pl)
DK (1) DK3999038T3 (pl)
ES (1) ES2974542T3 (pl)
FI (1) FI3999038T3 (pl)
HR (1) HRP20240200T1 (pl)
HU (1) HUE065712T2 (pl)
IL (1) IL289884B1 (pl)
LT (1) LT3999038T (pl)
MX (1) MX2022000708A (pl)
PH (1) PH12022550083A1 (pl)
PL (1) PL3999038T3 (pl)
PT (1) PT3999038T (pl)
RS (1) RS65302B1 (pl)
SI (1) SI3999038T1 (pl)
SM (1) SMT202400107T1 (pl)
TW (2) TW202116307A (pl)
WO (1) WO2021011808A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202400329T1 (it) 2018-01-19 2024-09-16 Cytokinetics Inc Analoghi di diidrobenzofurano e indene come inibitori di sarcomero cardiaco
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3843842A1 (en) 2018-08-31 2021-07-07 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2022187501A1 (en) 2021-03-04 2022-09-09 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MX2024000804A (es) 2021-07-16 2024-02-06 Cytokinetics Inc Metodos para tratar la miocardiopatia hipertrofica.
IL318470A (en) 2022-07-20 2025-03-01 Cytokinetics Inc Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス, インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025198687A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101305010A (zh) * 2005-09-01 2008-11-12 阿雷生物药品公司 Raf抑制剂化合物及其用法
RU2012115459A (ru) * 2009-09-18 2013-10-27 Санофи Таблетируюмый препарат (4'-трифторметилфенил)амида (z)-2-циано-3-гидрокси-бут-2-еноевой кислоты с улучшенной устойчивостью
NZ727015A (en) * 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2014205234A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
EP3151671A4 (en) * 2014-06-03 2018-03-07 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
US9963462B2 (en) * 2015-09-30 2018-05-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Sepiapterin reductase inhibitors
SMT202400329T1 (it) * 2018-01-19 2024-09-16 Cytokinetics Inc Analoghi di diidrobenzofurano e indene come inibitori di sarcomero cardiaco

Also Published As

Publication number Publication date
HUE065712T2 (hu) 2024-06-28
EP3999038B1 (en) 2024-01-10
FI3999038T3 (fi) 2024-02-21
ES2974542T3 (es) 2024-06-27
NZ784934A (en) 2025-03-28
AU2020315642A1 (en) 2022-03-03
CN114765954B (zh) 2024-01-02
HRP20240200T1 (hr) 2024-04-26
LT3999038T (lt) 2024-03-25
JP2022542804A (ja) 2022-10-07
PH12022550083A1 (en) 2023-04-12
IL289884B1 (en) 2025-09-01
SMT202400107T1 (it) 2024-05-14
SI3999038T1 (sl) 2024-05-31
IL289884A (en) 2022-03-01
US20220265612A1 (en) 2022-08-25
WO2021011808A1 (en) 2021-01-21
PT3999038T (pt) 2024-03-14
CA3144972A1 (en) 2021-01-21
CN114765954A (zh) 2022-07-19
DK3999038T3 (da) 2024-03-18
BR112022000495A2 (pt) 2022-03-03
TW202519217A (zh) 2025-05-16
EP3999038A1 (en) 2022-05-25
KR20220082804A (ko) 2022-06-17
MX2022000708A (es) 2022-02-23
RS65302B1 (sr) 2024-04-30
CL2022000108A1 (es) 2022-10-21
JP7623342B2 (ja) 2025-01-28
TW202116307A (zh) 2021-05-01

Similar Documents

Publication Publication Date Title
IL289884A (en) Oral formulations cardiac sarcomere inhibitors
GB202020117D0 (en) Oral cannabinoid formulations
SG11202101769YA (en) Cardiac sarcomere inhibitors
CA195311S (en) Toothbrush
CA194146S (en) Oral appliance
CA193061S (en) Toothbrush
IL291942A (en) Oral complement factor d inhibitors
CA193365S (en) Oral appliance
IL292682A (en) Formulation of x842 for oral administration
GB201915094D0 (en) New formulations
IL290356A (en) Formulations for Resotide
GB202117828D0 (en) New formulations
CA188766S (en) Oral appliance
GB201904338D0 (en) Fluorouracil-containing formulations
IL284691A (en) formulations
IL283593A (en) Bernaflam oral preparations
CA193063S (en) Toothbrush
HK40077275B (zh) 心脏肌节抑制剂口服制剂
HK40074726A (en) Cardiac sarcomere inhibitor oral formulations
CA208706S (en) Toothbrush
GB201910092D0 (en) New formulations
GB202114564D0 (en) Oral formulation
HK40055548A (en) Cardiac sarcomere inhibitors
HK40054614B (en) Cardiac sarcomere inhibitors
CA206245S (en) Toothbrush